Research and Clinical Trials on Venlafaxine (Effexor, Efexor)

avatar image
By Dr Greg Mulhauser

This list of current clinical research trials on Venlafaxine (Effexor, Efexor) is followed by a short set of abstracts from the most recent research articles published on the drug.

Article Contents

Venlafaxine (Effexor, Efexor) Clinical Research Trials

From our searchable database at ClinicalTrialsFeeds.org, this list includes all the latest information about clinical trials involving Venlafaxine (Effexor, Efexor).

 

Get These Clinical Trials as a Newsfeed

Venlafaxine:     Get the Venlafaxine clinical trials feed.    Add the Venlafaxine clinical trials feed to your My Yahoo! page.    Add the Venlafaxine clinical trials feed to your MyMSN page.

Current Research Literature on Venlafaxine (Effexor, Efexor)

Here are abstracts for some of the latest research articles to have appeared on Venlafaxine (Effexor, Efexor):

Comparative efficacy and acceptability of pharmacotherapeutic agents for anxiety disorders in children and adolescents: a mixed treatment comparison meta-analysis.

Curr Med Res Opin. 2009 Nov 11;
Uthman OA, Abdulmalik J
Abstract Objective: to compare efficacy and acceptability of different pharmacotherapeutic agents for treating anxiety disorders in children and adolescents Methods: A recently conducted Cochrane Review on pharmacotherapy for anxiety disorders in children and adolescents was updated. A mixed treatment comparison meta-analysis using Bayesian Markov Chain Monte Carlo simulation was used to perform the indirect comparison. We calculated relative risk ratios (RR) with 95% credible interval (CrI) using placebo as the common comparator. Results: Data were combined from 16 clinical trials that randomized children to six different treatment strategies, including placebo. Fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine were more efficacious than placebo. Venlafaxine was significantly less efficacious than fluvoxamine (RR = 0.60; 95% CrI 0.35-0.95) and paroxetine (RR = 0.65; 95% CrI 0.44-0.93). Fluoxetine, fluvoxamine, paroxetine, and sertraline had higher acceptability profile than placebo. Venlafaxine was less tolerated than fluvoxamine (RR = 0.16; 95% CrI 0.01-0.64), paroxetine (RR = 0.21; 95% CrI 0.05-0.59), and sertraline (RR = 0.31; 95% CrI 0.08-0.83). Fluvoxamine had a higher rate of clinical response and acceptability compared to other treatments in the network, with probability of 47.5% and 50.6% of being the most efficacious and well-tolerated treatment, respectively. Conclusion: Clinically important differences exist between commonly prescribed pharmacotherapeutic agents for treating anxiety among children in terms of both efficacy and acceptability in favor of fluvoxamine. Fluvoxamine might be the best choice when starting treatment for anxiety disorders among children and adolescents because it has the most favorable balance between benefits and acceptability.

[Serotonin-noradrenalin reuptake inhibitors in the treatment of non-malignant pain syndromes; a systematic review.]

Tijdschr Psychiatr. 2009; 51(11): 831-40
Vossen H, Monsieur D, van Os J, Leue C
BACKGROUND: Chronic pain and depressive symptoms are often comorbid. Antidepressants seem to influence not only the symptoms of depression but also the perception of pain. AIM: To give a systematic overview of the efficacy and safety of serotonin-noradrenalin reuptake inhibitors (snri) in the treatment of chronic non-malignant pain syndromes. methods We reviewed the literature by means of PubMed and PsycInfo using combinations of the words 'pain' 'venlafaxine' and 'duloxetine'. We selected clinical studies that investigated the influence of snris on pain perception. results Fourteen articles met our selection criteria. Medical conditions involved were fibromyalgia, diabetic neuropathy and post mastectomy pain. Twelve studies demonstrated the efficacy and safety of venlafaxine and duloxetine in the treatment of non-malignant pain. CONCLUSION: The results revealed that snris are effective in reducing pain particularly in the treatment of diabetic neuropathy. Results with regard to the other medical conditions are less clear. More research is needed to find out in which medical conditions snris have a significant pain reducing effect and why this effect does not hold in the case of other medical conditions.

[Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine]

Ginecol Obstet Mex. 2009 Oct; 77(10): 475-81
Lilue M, Palacios S
OBJECTIVE: To review the published data that include Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), especially desvenlafaxine, on vasomotor symptoms (VMS). METHODS: This review is based on published data in Medline (1990-2009) for studies on SSRI and SNRIs, especially desvenlafaxine, and VMS. RESULTS: There is increasing evidence that both norepinephrine and serotonin are associated with the communication and modulation of the temperature homeostasis maintained by the hypothalamus. Different studies demonstrated the modest efficacy of SSRIs and SNRIs on VMS. Recently, a program of clinical trials with desvenlafaxine (a salt from the major metabolite of venlafaxine) has been developed for VMS. Currently, there are three randomized, double-blind clinical trials published, showing a significantly higher efficacy of desvenlafaxine versus placebo on VMS. There were also increased minor side effects with desvenlafaxine, especially nausea, at the beginning of the treatment. CONCLUSIONS: A non-hormonal alternative--desvenlafaxine--has proven efficacy for VMS. There was also an increase in minor side effects, especially nausea, at the beginning of the treatment. There are clear subgroups of patients with VMS eligible, such as women with hormone-dependent cancers, women who do not want to be treated with hormone therapy or just want to get relief of their vasomotor symptoms.

[Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients]

Fortschr Neurol Psychiatr. 2009 Nov; 77(11): 646-54
Anghelescu IG, Dierkes W, Volz HP, Loeschmann PA, Schmitt AB
The therapeutic effects of venlafaxine extended release have been investigated by two prospective observational studies including 8506 patients in the outpatient setting of office based general practitioners and specialists. The efficacy has been documented by the Clinical Global Impression (CGI) scale and by the Hamilton depression (HAMD-21) scale. The tolerability has been assessed by the documentation of adverse events. About (2/3) of the patients were treated because of depression and about (1/3) mainly because of anxiety disorder. The patients of specialists did receive higher dosages and were more severely affected. The response rate on the CGI scale was 87.4 for the patients of general practitioners and 74.2 % for the patients of specialists. The results of the HAMD-21 scale, which has been used by specialists, showed a response rate of 71.8 and a remission rate of 56.3 %. These positive effects could be demonstrated even for the more severely and chronically affected patients. The incidence of adverse events was low in both studies and comparable to the tolerability profile of randomized studies. Importantly, the good tolerability profile was similar even for patients with concomitant cardiovascular disease. In conclusion, these results confirm the efficacy and good tolerability of venlafaxine extended release in the outpatient setting in Germany.

Advanced formulation design of venlafaxine hydrochloride coated and triple-layer tablets containing hypromellose.

Pharm Dev Technol. 2009; 14(6): 650-8
Gohel M, Bariya SH
The purpose of this research work was to develop venlafaxine hydrochloride-coated and layered matrix tablets using hypromellose adopting wet granulation technique. The granules and the tablets were characterized. The monolithic tablets were coated with different ratios of ethyl cellulose and hypromellose. The in vitro dissolution study was performed in distilled water. In the layered tablets, the middle layer containing drug was covered with barrier layers containing high viscosity grade hypromellose. Simplex lattice design was used for formulating the layered tablets. The dissolution study of the optimized batches and a reference product was carried out in 0.1 N HCl, phosphate buffer and hydroalcoholic solution. Burst drug release was exhibited by the uncoated tablets, probably due to high aqueous solubility of venlafaxine HCl. The coated tablets showed sustained drug release without burst effect. The drug release was best explained by Weibull model. A unified Weibull equation was evolved to express drug release from the coated tablets. The layered tablets also exhibited sustained release without burst effect due to effective area reduction. The optimized batches showed identical drug release in 0.1 N HCl, phosphate buffer and 10% v/v aqueous alcohol. Layered tablets may well be adopted by the industry due to the possibility of achieving a high production rate.

 

This page was last reviewed by Dr Greg Mulhauser, Monday, 1 June 2009.

The URL of this page is:
http://counsellingresource.com/medications/trials-and-research/venlafaxine-research.html